A Phase II study of Aprepitant in patients receiving chemotherapy included carboplatin for gynaecological cancer

Trial Profile

A Phase II study of Aprepitant in patients receiving chemotherapy included carboplatin for gynaecological cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Aug 2018

At a glance

  • Drugs Aprepitant (Primary) ; Azasetron; Dexamethasone
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Aug 2018 Results published in the Medical Science Monitor Journal.
    • 13 Aug 2018 Last checked against University Hospital Medical Information Network - Japan record.
    • 11 Aug 2018 Status changed from not yet recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top